Actively Recruiting
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
Led by Centre Hospitalier Universitaire de Besancon · Updated on 2024-11-21
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the types of cell death caused by extracorporeal photochemotherapy (ECP), a cell therapy used to modulate the immune system and induce tolerance. ECP is mainly used to control graft-versus-host disease (GVHD) after hematopoietic cell transplants, manage rejection in solid organ transplants, and treat cutaneous T-cell lymphoma. The study aims to clarify how ECP affects different cell types by analyzing the cell death mechanisms involved, which are currently not well understood. ECP involves repeated sessions where leukocytes are collected from the patient through apheresis, treated with a photosensitizer called 8-MOP, exposed to UVA light, and then reinfused. This closed-circuit process may help regulate immune responses differently depending on the disease context, such as promoting regulatory cells in GVHD and transplant rejection or activating anti-tumor responses in lymphoma. The study collects samples from the ECP circuit before and after treatment without additional punctures to analyze cell death types like necroptosis, apoptosis, pyroptosis, or autophagy. Participants will be adult patients who have received ECP treatment for at least one month for their respective conditions. The research includes detailed analysis of the cell death occurring within 24 hours after sensitization and irradiation. By examining cell death types and their timing, the study seeks to better understand how ECP works to resolve inflammation or fight tumors. The trial is sponsored by the Centre Hospitalier Universitaire de Besancon and will continue until July 2025.
CONDITIONS
Brief Title
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients
- Treated with extracorporeal photochemotherapy for at least 1 month
- Treatment indication includes control of graft-versus-host disease after hematopoietic cell allograft (acute or chronic)
- Treatment indication includes cellular or humoral rejection in solid organ transplantation (heart, lung, kidney)
- Treatment indication includes cutaneous T-cell lymphoma
You will not qualify if you...
- Subjects with limited legal capacity
- Subjects unlikely to comply with study procedures
- Subjects without social security coverage
- Pregnant women
- Subjects currently in exclusion period of another study or as per national clinical trial registry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Participants must have been treated with extracorporeal photochemotherapy for at least 1 month and meet other eligibility criteria.
Duration - Ongoing as per routine extracorporeal photochemotherapy treatment
Participants undergoing extracorporeal photochemotherapy have blood samples collected from the photochemotherapy circuit before and after sensitization and UVA irradiation to study cell death mechanisms.
Sampling occurs during photochemotherapy sessions without additional punctures
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire de Besançon
Besançon, France, 25000
Actively Recruiting
Research Team
C
Charline VAUCHY, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here